2022-08-21 高雄萬豪酒店 10F皇喜會議室 10D-1
| 時間 | 主題 | 講者 | 座長 | 摘要 | 簡報 |
|---|---|---|---|---|---|
13:10 ~ 13:20 |
PD09-1: The real-world outcome with Abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer treated in China Medical University Hospital |
蔡正晏 |
黃昭淵, 高建璋 |
||
13:20 ~ 13:30 |
PD09-2: Preoperative MRI and clinical factors are predictors for biochemical recurrence in high and very high risk prostate cancer |
楊晨洸 |
黃昭淵, 高建璋 |
||
13:30 ~ 13:40 |
PD09-3: Could 18F-FluciclovinePET/CT be a game changer in prostate cancer with biochemical recurrence? |
胡蔚祥 |
黃昭淵, 高建璋 |
||
13:40 ~ 13:50 |
PD09-4: Efficacy of immune check point inhibitors in metastatic urothelial carcinoma is associated with chemotherapy response, a real world retrospective study |
陳韋辰 |
黃昭淵, 高建璋 |
||
13:50 ~ 14:00 |
PD09-5: Perineural invasion can predict prognosis for upper tract urothelial carcinoma following radical nephroureterectomy |
陳怡璇 |
黃昭淵, 高建璋 |
||
14:00 ~ 14:10 |
PD09-6: Initial antibiotics choice may not be associated with the prognosis of fournier’s gangrene |
張哲綱 |
黃昭淵, 高建璋 |